Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Sant Kumar Verma"'
Autor:
Sant Kumar Verma, Suresh Thareja
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0175318 (2017)
Aldose reductase (ALR2) inhibition is the most legitimate approach for the management of diabetic complications. The limited triumph in the drug development against ALR2 is mainly because of its close structural similarity with the other members of a
Externí odkaz:
https://doaj.org/article/d6835ccbe06c4048bbbd24d3ec7e44ff
Publikováno v:
Letters in Drug Design & Discovery. 20:793-807
Background: Cancer is the world's second largest cause of death and is responsible for an estimated 9.6 million mortalities in 2018. Poly-ADP-ribose polymerases (PARPs) are enzymes and family of proteins, involved in many cellular processes, includin
Publikováno v:
Journal of Biomolecular Structure and Dynamics. :1-23
Dual aromatase-steroid sulfatase inhibitors (DASIs) lead to significant deprivation of estrogen levels as compared to a single target inhibition and thereby exhibited an additive or synergistic effect in the treatment of hormone-dependent breast canc
Autor:
Shivanshu Pandey, Sitanshu Mondal, Kumari Kajal, Balak Das Kurmi, Sant Kumar Verma, Preeti Patel
Publikováno v:
Archiv der Pharmazie.
Autor:
Sukhbir Singh Gill, Tanish Goyal, Megha Goswami, Preeti Patel, Ghanshyam Das Gupta, Sant Kumar Verma
Publikováno v:
Environmental Science and Pollution Research.
Publikováno v:
Environmental Science and Pollution Research. 29:53934-53953
Water is an essential moiety for the human use since a long time. Availability of good-quality water is very essential, as it is used in almost all the industrial, agricultural, and household activities. However, several factors such as increased urb
Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies
Publikováno v:
Journal of Controlled Release. 341:782-811
Brain, a subtle organ of multifarious nature presents plethora of physiological, metabolic and bio-chemical convolutions that impede the delivery of biomolecules and thereby resulting in truncated therapeutic outcome in pathological conditions of cen
Autor:
Sant Kumar Verma, Shalini Jaswal, Priya Bisht, Rajiv Patel, Darakhshan Parveen, Ghanshyam Das Gupta
Publikováno v:
Letters in Drug Design & Discovery. 20
Background: Tirzepatide (LY3298176) was approved by U.S. Food and Drug Administration (FDA) on May 13th, 2022. The drug was developed by Eli Lilly and Co. and marketed under the trade name of ‘Mounjaro’, a first-in-class ‘Twincretin’, which i
Autor:
Sitanshu Mondal, Vivek Asati, Sant Kumar Verma, Ghanshyam Das Gupta, Balak Das Kurmi, Preeti Patel
Publikováno v:
SEPARATION SCIENCE PLUS. 6
Publikováno v:
Letters in Drug Design & Discovery. 20
Background: Protein tyrosine phosphatase 1B (PTP 1B) is a recognized legitimate target for type 2 diabetes and obesity, collectively designated as ‘diabesity’, even though first-in-class inhibitor is still awaited. The main cause behind the unach